Curriculum Vita
 Ciarán P. Kelly, MD
Associate Professor of Medicine
GENERAL INFORMATION
Date Prepared: May, 2005
Name: Ciarán P. Kelly
Office Address:
Division of Gastroenterology,
Dana 601,
Beth Israel Deaconess Medical Center,
330 Brookline Avenue,
Boston, MA 02215.
Telephone:
(617) 667 1264
(617) 667 1272 (Admin)
Fax: (617) 975 5071
e-mail: ckelly2@bidmc.harvard.edu
Education:
1980 B.A. (Medical Sciences) Dublin University, Trinity College, Dublin
1882 M.B., B.Ch., B.A.O. - 1st Class Honors. Dublin University, Trinity College, Dublin
1995 M.D. (by thesis) Dublin University, Trinity College, Dublin
Postdoctoral Training:
1982-1983 Intern Medicine Federated Dublin Voluntary Hospitals
1983-1984 Resident Internal Medicine Federated Dublin Voluntary Hospitals
1985 Fellow Gastroenterology Federated Dublin Voluntary Hospitals
1986 Resident Pediatric Internal Medicine The Children's Hospital, Dublin
1986-1987 Fellow Pulmonary Medicine St. James' Hospital, Dublin
1987-1989 Fellow Gastroenterology St James' Hospital, Dublin
Licensure and Certification:
1982-1992 Medical Licensure, Medical Council of Ireland
1985 Member, Royal College of Physicians of Ireland
1986 Diploma of Child Health, Royal College of Surgeons of Ireland
1987 Member, Royal College of Physicians, United Kingdom
1987 ECFMG Certification
1991 Massachusetts Medical Licensure
1995 Diplomate in Internal Medicine, American Board of Internal Medicine
1996 Fellow of the Royal College of Physicians of Ireland
1997 Diplomate in Gastroenterology, American Board of Internal Medicine
2001 Fellow of the American College of Gastroenterology
Academic Appointments:
1985-1986 Tutor, Clinical Medicine Dublin University, Trinity College, Dublin
1986-1989 Lecturer, Clinical Medicine Dublin University, Trinity College, Dublin
1989-1995 Assistant Professor of Medicine Boston University School of Medicine
1995-1996 Associate Professor of Medicine Boston University School of Medicine
1996-2001 Assistant Professor of Medicine Harvard Medical School, Boston
2001 - Associate Professor of Medicine Harvard Medical School, Boston
Hospital Appointments:
1989-1996 Attending Physician, Boston University Medical Center
1989-1996 Attending Physician, Boston City Hospital
1992-1996 Attending Physician, Boston V.A. Medical Center
1996- Associate Physician, Beth Israel Deaconess Medical Center
2005- Biologist, Pediatric Mucosal Immunology, Massachusetts General Hospital
Beth Israel Deaconess Medical Center Service Responsibilities:
1996-current Gastroenterology Service Attending
1997-2001 Internal Medicine Service Attending
1997-current Director, Gastroenterology Subspecialty Fellowship Training
2001-current Chief, Herrman L. Blumgart Internal Medicine Firm
2004-current Medical Director, Celiac Center
Beth Israel Deaconess Medical Center Committee Assignments (1996 to current):
1996-2003 Selection Committee, Internal Medicine Residency Training Program
1997-current Chair, Selection Committee, Gastroenterology Fellowship Training Program, BIDMC
2002-current NIH, General Clinical Research Center, Scientific Advisory Committee
2001-current Medical Patient Care Committee
2003-2004 Education Strategic Review Committee (GME subcommittee)
2001-current Competency Committee, Internal Medicine Residency Training Program
2004-current Curriculum Committee, Internal Medicine Residency Training Program
Committee Assignments (1996 to current):
National & International
• 1996-1998 Abstract Review Committee Member, Digestive Disease Week, American Gastroenterological Association
• 1999-2004 Abstract Review Committee, Chairperson, Digestive Disease Week, American Gastroenterological Association
• 1998 Review Committee Member, Research Grants. Medical Research Council, London, U.K.
• 2000 Review Committee Member, Research Grant Proposals. The Health Research Board, Dublin, Ireland.
• 2000 Review Committee Member, Clinical Research Training Fellowships. The Health Research Board, Dublin, Ireland.
• 2001 Ph.D. Examination Committee, Denise Drudy BSc, University College Dublin.
• 1999-2001 External Reviewer, Research Grant Proposals – Infection & Immunity Section. The Wellcome Trust, London, U.K.
• 2003 External Reviewer, Research Grant Proposals, Science Foundation Ireland
• 2000-current Councilor, Intestinal Disorders Section, American Gastroenterological Association
• 2001-2004 Member, American Gastroenterological Association, Committee on Education
• 2001-2004 Member, American Gastroenterological Association, DDW, Program Evaluation Sub-committee
• 1999-2001 Study Section ad hoc Member, NIH, CSR, Bacteriology & Microbiology-1.
• 2000-2004 Member, NIH, CSR, Special Emphasis Panels
• 2000-2004 Member, Bacteriology & Mycology-1 Study Section, NIH, CSR.
• 2003-2004 Organizing Committee, NIH Consensus Conference on Celiac Disease
• 2004- Scientific & Medical Advisory Board, National Foundation for Celiac Awareness
• 2005 Food & Drug Administration, Center for Food Safety and Applied Nutrition Advisory Committee on "Approaches to establish thresholds for major food allergens and for gluten in food"
• 2005 Scientific Reviewer, IRCSET, Postdoctoral Fellowship Scheme
• 2005- Host Interactions with Bacterial Pathogens Study Section, NIH, CSR
Regional:
• 1997 Review Committee Member, Pilot Feasibility Study Grants. NIH, NIDDK, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School.
• 1998 Grant Review Committee Member. NIH, NIDDK, Harvard Digestive Diseases Center.
• 1999 Grant Review Committee Member (Mentored Clinical Scientist Development Award). Division on Aging, Harvard Medical School
• 2001-2003 Scientific Advisory Board, Harvard – Thorndike Clinical Research Center, BIDMC
• 2003 Grant Reviewer, Center for Integration of Medicine and Innovative Technology, Brigham and Women's Hospital, Harvard medical School.
• 2003 Pilot/Feasibility Grant Reviewer, Harvard Disestive Diseases Center, Harvard Medical School, Children’s Hospital, Brigham and Women's Hospital, and BIDMC, Boston.
Professional Societies
1985 Royal College of Physicians of Ireland, Member
1987 Royal College of Physicians (United Kingdom), Member
1992 American Gastroenterological Association, Member
1994 Crohn’s & Colitis Foundation of America, Member
1995 Mucosal Immunology Society, Member
2001 American College of Gastroenterology, Fellow
Leadership Roles - American Gastroenterological Association:
1995–1998 Member, Research abstract selection committee
1996-2002 Invited Speaker, "Meet-the-Professor" Sessions
1996–2004 Chair/Moderator, Research Symposia
1997–2004 Chair/Moderator, Clinical Symposia,
1998–2000 Delegate, Intestinal Disorders Section
1999–2004 Chair, Research Abstract Selection Committee
2000, 2004 Faculty Member, Postgraduate Course
2000-2004 Councilor, Intestinal Disorders Section
2001-2004 Member, Committee on Education
2003-current Senior Author, Graduate Teaching Project on Celiac Disease
Editorial Boards:
1999 – 2004 Inflammatory Bowel Diseases
2002 – current Clinical Gastroenterology and Hepatology
2003 – current American Journal of Physiology: Gastrointestinal & Liver Physiology
1997-2005 ad hoc Reviewer: American Journal of Gastroenterology
1997-2004 ad hoc Reviewer: American Journal of Physiology
1998,1999 ad hoc Reviewer: Antimicrobial Agents & Chemotherapy
2000 ad hoc Reviewer: Bone Marrow Transplantation
1997 ad hoc Reviewer: Clinical Immunology
1998-2005 ad hoc Reviewer: Digestion
2000-2003 ad hoc Reviewer: Digestive Diseases and Sciences
1996-2005 ad hoc Reviewer: European Journal of Gastroenterology & Hepatology
1996-2003 ad hoc Reviewer: Gastroenterology
1998-2003 ad hoc Reviewer: Gut
1999-2003 ad hoc Reviewer: Infection and Immunity
2005 ad hoc Reviewer: Journal of Clinical Gastroenterology & Hepatology
2000 ad hoc Reviewer: Journal of Clinical Investigation
2005 ad hoc Reviewer: Journal of Immunology
2000 ad hoc Reviewer: Journal of Virology
1995, 1998 ad hoc Reviewer: Lancet
2001-2005 ad hoc Reviewer: New England Journal of Medicine
2000 ad hoc Reviewer: Oncogene
1998 ad hoc Reviewer: Western Journal of Medicine
Awards and Honors:
School of Medicine, Dublin University, Trinity College, Dublin:
1979 - 1982 Foundation Scholar
1978 Dr Henry Hutchinson Stewart Scholarship
1978 Andrew Francis Dixon Scholarship
1979 Daniel John Cunningham Memorial Prize & Medal
1980 John Mallet Purser Medal
1980 Welland Prize
1982 Gold Medal
1982 Fitzpatrick Scholarship
1982 G B McHutchinson Bequest
1982 Sir James Craig Memorial Prize
1982 Arthur Ball Prize
1982 De Renzy Centenary Prize
1982 Professor's Prize, Obstetrics & Gynaecology
1982 Reuben Harvey Prize
1989 - 1990 Postgraduate Travelling Scholarship
1989 Shep.ard Memorial Prize
1989 Sir John Banks Research Medal
1992 Career Development Award, Crohn's and Colitis Foundation of America
1992 Research Scholar Award, American Gastroenterological Association
1993 Clinical Investigator Award, National Institutes of Health, NIDDK
1996 Fellowship, Royal College of Physicians of Ireland
2001 Fellowship, American College of Gastroenterology
RESEARCH, TEACHING AND CLINICAL CONTRIBUTIONS
A. Narrative Report:
My research focuses on the pathogenesis of gastrointestinal infectious and inflammatory disorders. I have a longstanding interest in the host immune response to Clostridium difficile, the etiologic agent of antibiotic-associated diarrhea and pseudomembranous colitis (New Eng J Med, 1994;330:257-262). My research has shown that a systemic humoral immune response to C. difficile toxin A is associated with natural protective immunity against C. difficile (New Eng J Med, 2000;342:390-397 & Lancet 2001;357:189-193). This important finding has opened the way to the development and testing of novel passive and active immunization regimens to prevent and treat C. difficile diarrhea and colitis. We have also shown that leukocyte activation by C. difficile toxins is an integral component of the pathophysiology of C. difficile enterocolitis (J Clin Invest 1994;1257-1265). We also find that the pro-inflammatory effects of C. difficile toxins result from the activation of NF-kB and MAP kinase signaling pathways by a mechanism independent of their previously described rho-glucosylation activity (J Clin Invest 2000;105:1147-1156).
In a second research project my laboratory examines the regulation of chemotactic cytokine (chemokine) gene expression in gastrointestinal epithelial cells. We have shown that contact with the gastric pathogen Helicobacter pylori activates MAP kinase and NF-kB signal transduction pathways in gastric epithelial cells leading to IL-8 gene transcription (Gastroenterology 1997:113;1099-1109). Furthermore, gene products encoded by the H. pylori cag pathogenicity island are required for NF-kB, p38 and JNK MAP kinase activation (J Immunol, 1999;163:5552-5559) and for gastric epithelial cell EGF receptor transactivation (J Biol Chem, 2001; 276:48127-48134). Infection by cag+ strains of H. pylori is associated with a greater risk for peptic ulcer disease and gastric cancer. Since the NFkB, MAP kinase and EGFR pathways regulate cell proliferation, differentiation, programmed death, stress and inflammatory responses their activation by H. pylori cag+ strains may be instrumental in the pathogenesis of gastroduodenal inflammation, ulceration and neoplasia.
I am actively involved in undergraduate medical education and, in addition to teaching on the clinical service, I am a Faculty member for a variety of ongoing HMS courses including: "Integrated Human Physiology", "Human Systems: Gastrointestinal Pathophysiology", "Core I, Medical Lecture Series", "Advanced Biomedical Science Course", and "Everything you always wanted to know from core medicine but were afraid to ask (HST 330)". I have been the Director of the 3-year, ACGME-approved, Gastroenterology Fellowship Training Program at BIDMC since 1997. In that role I coordinate the recruitment, clinical and research training and accreditation of 15 to 20 Gastroenterology trainees annually. In 2000, I was honored to assume the role of Chief of the Herrman L. Blumgart, Internal Medicine Firm. As Firm Chief I oversee the clinical training of Residents assigned to one of our four Internal Medicine firms, hold regular teaching ward rounds and run our weekly Firm Conference. Finally, I am a Faculty member for a variety of popular annual HMS, CME courses including "Update in Internal Medicine" and "Comprehensive Review of Gastroenterology".
I have served on grant review committees for the NIH, the Wellcome Trust (U.K.), The Health Research Board (Ireland) and for a number of local NIH-sponsored center grants. I served on the organizing committee of the 2004 NIH Consensus Development Conference on Celiac Disease. I am an active member of the American Gastroenterology Association and have assumed a number of leadership roles in that association (Chair of Abstract Review Committees, Chair of Clinical and Research Symposia, Councilor, Education Committee Member, Invited Speaker at Annual Meetings). My clinical activities are primarily in the subspecialty of Gastroenterology. I have special interests in the treatment of C. difficile colitis, inflammatory bowel disease, H. pylori gastritis, peptic ulcer disease, gastroesophageal reflux disease and gluten-sensitive enteropathy (celiac disease) and I have authored clinical review articles on these topics for major medical journals and textbooks.
B. Funding Information:
Current Funding (National Institutes of Health):
2001-2006 NIH, NIDDK (R01-DK 58858), Principal Investigator
"Leukocyte recruitment in inflammatory bowel disease".
2004-2009 NIH, NIAID (R01-AI53069), Principal Investigator
"Immune response to Clostridium difficile"
2005-2010 NIH, NIDDK, Program Project DK 33506
Barrier Function of the GI Tract in Health and Disease
Project 5: Principal Investigator
Saccharomyces boulardii anti-inflammatory factor in intestinal inflammation
2001-2006 NIH, NIDDK (R01-DK 60729), Co-Investigator
"Mechanisms of colonic response to neurotensin"
2000-2005 NIH, K23 AG00971 Sponsor (PI/trainee, Lorraine Kyne, M.D.)
"Aging and the human antibody response to C. difficile"
2000-2005 NIH, K23 DK02848 Sponsor (PI/trainee, Richard Farrell, M.D.)
"MDR-1 expression in inflammatory bowel disease"
Under Review (National Institutes of Health):
1998-2003 NIH, NIDDK (R01-DK 54920), Principal Investigator
"Pathogenic mechanisms of Helicobacter pylori gastritis ".
2005-2007 NIH, NIDDK (R21)
Animal models of celiac disease Co-investigator
Current Funding (Sponsored Research):
2004-2005 Serology testing for H. pylori in healthy human volunteers
Sponsor: ActivBiotics Principal Investigator
2004-2005 Measurement of the bacterial burden in gastric H. pylori infection
Sponsor: ActivBiotics Principal Investigator
2004-2005 Rifalazil in H. pylori gastritis
Sponsor: ActivBiotics Principal Investigator
2004-2005 CDA1 a human monoclonal antibody against Clostridium difficile toxin A:
Sponsor: Massachussets Biologics Laboratory Principal Investigator
2004-2005 Helicobacter pylori phototherapy system Principal Investigator
Sponsor: LumeRx
2001-2004 GERD and asthma in women Co-investigator
Sponsor: Janssen Pharma
2004-2005 Effect of Rifaximin in treatment and prevention of Clostridium difficile associated diarrhea and colitis in hamsters
Sponsor: Salix Principal Investigator
Previous Funding:
1989-1991 The University of Dublin, Trinity College Principal Investigator
Postgraduate Scholarship: "Pathogenic mechanisms in C. difficile colitis"
1989-1992 1990-1991 Boston University Medical Center Hospital Principal Investigator
Research Grant: "Clostridium difficile anti-toxin antibody in man".
1989-1993 Crohn's and Colitis Foundation of America Principal Investigator
Career Development Award: "Cellular Adhesion Molecule Expression in IBD".
1989-1994 American Gastroenterology Association Principal Investigator
Research Scholar Award "Cellular Adhesion Molecule Expression in IBD ".
1989-1995 GalaGen Incorporated Principal Investigator
Research Grant: "Anti-Clostridium difficile Bovine Immunoglobulin Concentrate."
1993-1998 National Institutes of Health, NIDDK (KO8, DK-02128), Principal Investigator
Clinical Investigator Award (KO8): "Cellular Adhesion Molecule Upregulation in Inflammatory Bowel Disease".
1996-1998 Crohn's and Colitis Foundation of America, Principal Investigator
Research Grant: "IL-16 in intestinal inflammation".
1999-2001 Crohn's and Colitis Foundation of America, Principal Investigator
"Regulation of enterocyte chemokine production in intestinal inflammation".
1997-2002 NIH, NIDDK (R29-DK3706) Co-investigator, (PI: Pierre Michetti, M.D.)
"Natural and induced immunity against Helicobacter pylori".
1994-2003 Biocodex Inc. Principal Investigator
"Saccharomyces boulardii and immune responses to Clostridium difficile"
2001-2003 Acambis Inc. Principal Investigator
"Safety and immunogenicity of a candidate Clostridium difficile toxoid vaccine"
C. Director, Postgraduate Studies:
1999-2000 Thesis Director: Harvard University,
William Brazer, B.A., Master of Liberal Arts
"Determining the functional active site on CD4 for interleukin-16"
1996-2000 Research Supervisor (External): Catholic University of Louvain, Belgium
Michel Warny, M.D. Doctor of Philosophy
"Immune responses to Clostridium difficile toxins"
1998-2002 Director of Studies (External), University of Wolverhampton, School of Health Sciences, U.K.
Sarah Keates, B.Sc., Doctor of Philosophy
"Gastric epithelial cell activation by Helicobacter pylori"
2005- Research supervisor and thesis committee (external)
Northeastern University, Boston
Jessica Glass, Ph.D. candidate
"Psychological factors influencing dietary compliance in Celiac Disease"
D. Report of Teaching:
1. Local contributions:
a) Harvard Medical School
2001-2005
Chief, Herrman L Blumgart, Internal Medicine Firm
3-8 students during each block rotation
75 hours of contact time (3 hours wee
Human Systems Module IIA Gastroenterology kly)
1996-2005
Lecturer "Diarrhea and malabsorption"
100 medical students
1 hour lecture, 4 hours preparation
1996-2002
Human Systems Module IIA Gastroenterology
Minicase / Focused Discussion leader
10-20 medical students
1 hour tutorial, 2 hours preparation
1997-2005
Core Clerkship in Medicine
Lecturer
15 - 20 medical students
3 hours of contact (3, 1 hour lectures each academic year), 3 hours preparation
1997-2005
Introduction to the abdominal exam
Focused clinical exercise leader
5 - 6 medical students
2 hour tutorial, 1 hour preparation
1996-2004
Visit Attending, General Medicine Service
2-4 medical students
20 hours of contact time (5 hours weekly for 4 weeks)
1999
Advanced Biomedical Science Course
"Biology of Solid Tumor Progression"
Discussion leader
12 medical students
2 hour tutorial, 2 hours preparation
2000
Visit Attending, Ludwig-Maximilian University / HMS Rotation
3 medical students
20 hours of contact time (5 hours weekly for 4 weeks)
2000-2002
Integrated Human Physiology IN 712
Focused exercise leader
10-20 medical students
1 hour tutorial, 2 hours preparation
1998-2004
HST 330 "Everything you always wanted to know from core medicine but were afraid to ask"
Discussion Leader
8 - 10 medical students
12 hours of contact time (3, 2 hour tutorials, bi-annually), 6s hour preparation
1. Local contributions:
b) Graduate Medical Education
1997-2004
Director, Gastroenterology Fellowship Training Program
8-10 Fellows
200 hours of contact time (4 hours weekly)
100 hours administration (2 hours weekly)
2001-2004
Chief, Herrman L Blumgart, Internal Medicine Firm
30-45 Residents
200 hours of contact time (4 hours weekly)
25 hours administration (1/2 hour weekly)
1996-2004
Visit Attending, General Medicine Service
8-10 internal Medicine Residents
60 hours of contact time (15 hours weekly for 4 weeks)
1996-2001
BIDMC, Medical Firm Conference
Consultant/invited speaker: Clinical teaching conference
10 – 15 Residents, 5 - 10 Medical Students, 5 – 10 Faculty
18 hours of contact time (12, 1.5 hour sessions, monthly), 1 hour preparation
1996-2003
BIDMC, Thorndike Medical Rounds
Lecturer
25 – 40 Residents, 10 - 15 Medical Students
1 hour lecture, 1 hour preparation
1997-2002
Ambulatory Medicine Core Curriculum
Lecturer
20 – 25 Residents, 10 - 15 Medical Students
3 hours of lecture time, 2 hours preparation
1997-2001
BIDMC, Update in Gastroenterology
Course Director (and Lecturer)
50 Gastroenterology Fellows
2 day course, 20 speakers
1. Local contributions:
c) Continuing Medical Education
1997-2005
Update in Internal Medicine
Faculty Member / Lecturer
500 – 750 Internal Medicine Physicians
1 hour lecture, 3 hours preparation
1997-2005
Comprehensive Review of Gastroenterology
Faculty Member / Lecturer
150 – 250 Gastroenterologists
2-3 hours of lecture time, 9 hours preparation
1997
Primary Care for the Obstetrician / Gynecologist
Faculty Member / Lecturer
200 Obstetrician / Gynecologists
1 hour lecture, 3 hours preparation
2000
Primary Care Internal Medicine: Principles & Practice
Faculty Member / Lecturer
300 Primary Care Physicians
1 hour lecture, 3 hours preparation
2001
Current diagnosis and management of gastrointestinal motility disorders and irritable bowel syndrome
Faculty Member / Lecturer
50 Gastroenterologists
1 hour lecture, 3 hours preparation
2. Regional, National and International Contributions:
1996 American Gastroenterology Association, Annual Meeting, San Francisco, CA
"Pseudomembranous colitis"
"Meet-the-Professor" session
1996 Boston University Medical Center, 1996
"Inflammatory Bowel Disease"
Lecturer: Gastroenterology Update CME Course
1997 Metrowest Medical Center, Framingham, MA
"Dyspepsia"
Residents’ Report
1998 Buenos Aires, Argentina
Harvard International "Gastroenterology Update"
Faculty Member / Lecturer
1998 Metrowest Medical Center, Framingham, MA
"Pseudomembranous colitis"
Residents’ Report
1999 Metrowest Medical Center, Framingham, MA, 1999
"Inflammatory Bowel Disease"
Residents’ Report
2000 American Gastroenterology Association, Annual Postgraduate Course, San Diego, CA
"Approach to chronic diarrhea"
"Clinical Challenges" Presentation
2000 Core Curriculum in Adult Primary Care Medicine, Dedham MA
"Celiac and other chronic diarrheal diseases"
2000 Metrowest Medical Center, Framingham, MA
"Gastroesophageal reflux disease"
Residents’ Report
2001 Conexao Medica, Sao Paulo, Brazil
Harvard Medical International "Men’s Health – Continuing Medical Education Course"
Faculty Member / Lecturer
2001 Conexao Medica, Sao Paulo, Brazil
"Gastroesophageal reflux disease" and "Peptic ulcer disease"
Faculty member / Lecturer
2001 Metrowest Medical Center, Framingham, MA
"GERD and Peptic Ulcer Disease"
Residents’ Report
2002 Metrowest Medical Center, Framingham, MA
"Gastroesophageal reflux disease"
Residents’ Report
2002 New York, NY
NewYork-Presbyterian Hospital, Columbia University &
BIDMC, Harvard Medical School
Update and Review of Internal Medicine
Faculty Member / Lecturer
2003 New York, NY
NewYork-Presbyterian Hospital, Columbia University &
BIDMC, Harvard Medical School
Update and Review of Internal Medicine
Faculty Member / Lecturer
GERD and Peptic Ulcer Disease
Diarrhea and Malabsorption
2003 Lahey Clinic
Current Topics in Gastroenterology & Hepatology
Guest Faculty
Celiac Disease
2004 Brigham & Women’s Hospital, Boston, MA
"Helicobacter pylori: Clinical Update".
Review of Infectious Diseases for the Primary Care Physician
2004 NewYork-Presbyterian Hospital, Columbia University & BIDMC, Harvard Medical School, New York, NY
"Gastroesophageal Reflux Disease & Peptic Ulcer Disease."
Update in Internal Medicine
2004 NewYork-Presbyterian Hospital, Columbia University & BIDMC, Harvard Medical School, New York, NY
"Evaluation of Chronic Diarrhea."
Update in Internal Medicine
2004 Massachusetts General Hospital, Boston, MA
"Disorders of the Foregut".
Update in Internal Medicine
2004 Mexico City, Mexico
"Gastroesophageal Reflux Disease."
Harvard Medical School CME Program on Internal Medicine
2004 Mexico City, Mexico
"Irritable Bowel Syndrome."
Harvard Medical School CME Program on Internal Medicine
2005 Mexico City, Mexico
"Gastroesophageal Reflux Disease."
Harvard Medical School CME Program on Internal Medicine
2005 Mexico City, Mexico
"Inflammatory Bowel Disease."
Harvard Medical School CME Program on Internal Medicine
2005 BIDMC
"Helicobacter pylori: from birth to grave."
Gastroenterology Core Curriculum
2005 New York, NY
"Gastroesophageal Reflux Disease & Peptic Ulcer Disease."
BIDMC & Columbia University CME Program
Update in Internal Medicine
2005 New York, NY
"Evaluation of Chronic Diarrhea."
BIDMC & Columbia University CME Program
Update in Internal Medicine
Invited Lectures:
1996 Massachusetts General Hospital, Boston, MA
"Clostridium difficile"
Gastroenterology Grand Rounds
1996 European Helicobacter pylori Study Group, Galway, Ireland
"Epithelial cell NF-kB activation in H. pylori gastritis"
Speaker: Helicobacter pylori and Host Response Research Meeting
1996 Coloproctology Study Group, St Vincent’s Hospital, University College Dublin, Ireland
"Clostridium difficile"
1996 Rhode Island Hospital, Brown University School of Medicine, Providence, RI
"Clostridium difficile colitis"
Gastroenterology Grand Rounds
1996 New England Society of Gastroenterology, Burlington, MA 1996
"GERD, dysphagia, & chest pain"
1996 "Bassett Healthcare, Cooperstown, NY
"Clostridium difficile"
Medicine Grand Rounds
1996 Whidden Memorial Hospital, Melrose, MA
"Inflammatory Bowel Disease"
Medicine Grand Rounds
1997 Hale Hospital, Haverhill, MA
"Inflammatory Bowel Disease"
Medical Grand Rounds
1997 United European Gastroenterology Association Annual Meeting, Birmingham, U.K.
"The immune response to C. difficile toxins
1997 Massachusetts General Hospital, Boston, MA
"Helicobacter pylori - gastric epithelial cell interaction"
Center for the Study of Inflammatory Bowel Disease – Annual Workshop
1997 St Elizabeth’s Hospital, Tufts University Medical School, MA, 1997
"Clostridium difficile" Lecturer: Seminars in Gastroenterology
1997 Hale Hospital, Haverhill, MA
"Helicobacter pylori and peptic ulcer disease"
Medical Grand Rounds
1998 American Gastroenterology Association, Annual Meeting, Washington, DC
"Pathogenesis of Helicobacter pylori gastritis"
1998 Massachusetts General Hospital, Boston, MA 1998
"Celiac sprue"
Gastroenterology Grand Rounds
1998 Greek Helenic Society, Athens, Greece
"Helicobacter pylori and pathogenesis of peptic ulcer disease"
1998 Celiac Society Annual Meeting, Warwick, RI
"Serological Testing for Celiac Disease"
1998 New Britain Hospital, University of Connecticut, CT
"Helicobacter pylori"
Medical Grand Rounds
1999 Beth Israel Deaconess Medical Center, Boston
"Clostridium difficile: Beyond Antibiotics"
Medicine Grand Rounds
1999 Beth Israel Deaconess Medical Center, Boston
"Clostridium difficile colitis"
Surgery Grand Rounds
1999 BIDMC, Women’s Health Seminar, Palm Beach, FL
"Gastrointestinal disorders in women: a journey through inner space"
1999 St Elizabeth’s Hospital, Tufts University Medical School, MA, 1999
"Helicobacter pylori regulation of gastric epithelial cell IL-8 production"
Research Symposium
1999 Boston MA, "Meet the Professor"
Gastroenterology Fellows’ Clinical Symposium
1999 New England Medical Center, Tufts University Medical School, MA
"The immune response to C. difficile toxins
Combined Gastroenterology & Infectious Disease Grand Rounds
1999 Hale Hospital, Haverhill, MA
"Gastroesophageal Reflux Disease"
Medical Grand Rounds
1999 Catholic Medical Center, Manchester, NH
"Peptic Ulcer Disease"
Medical Grand Rounds
2000 American Gastroenterology Association, Annual Meeting, San Diego, CA
"Pseudomembranous colitis"
"Meet-the-Professor" Session
2000 American Gastroenterology Association, Annual Meeting, San Diego, CA
"GI infections"
Focused Clinical Update
2000 Dublin University, Trinity College Medical School, Dublin, Ireland
"Clostridium difficile colitis"
2000 Caritas Norwood Hospital, Norfolk, MA
"Gastroesophageal Reflux Disease"
Medical Grand Rounds
2000 Hale Hospital, Haverhill, MA
"Update on Helicobacter pylori: Diagnosis and Treatment"
Medical Grand Rounds
2000 Amelia Island, FL
"Signal Transduction Pathways in Immune and Inflammatory Cells"
Crohn’s & Colitis Foundation National Conference, Discussant
2001 Norwood, MA
"Diagnosis of celiac disease: from 50 A.D. to 2001 A.D."
Celiac Society of America, "Healthy Villi" Chapter
2001 University of Virginia, Charlottesville, VA
"Regulation of ENA-78 gene expression in intestinal epithelial cells"
Immunogenetic mechanisms of intestinal inflammation, Invited Speaker
2001 Children’s Hospital, Boston, MA
"Update on celiac disease"
Children’s Hospital Celiac Support Group
2001 Wilmington Gut Club, Wilmington, NC
"Chronic diarrhea: Diagnosis and Therapy"
2001 Duke University Medical Center, Durham NC
"Clostridium difficile diarrhea: beyond antibiotics"
Gastroenterology Division Visiting Professor
2001 Landmark Medical Center, Woonsocket, RI
"Gastroesophageal Reflux Disease"
Medical Grand Rounds
2001 American Gastroenterology Association, Annual Meeting, Atlanta, GA
"H. pylori genome: Implications for understanding bacterial-host interactions
Invited speaker
2001 St Vincent’s Hospital, University College Dublin, Ireland
Regulation of gastric epithelial cell IL-8 gene expression by Helicobacter pylori"
Invited speaker
2001 Massachusetts General Hospital, Gastroenterology Rounds
"Clostridium difficile diarrhea: beyond antibiotics"
2001 Winchester Hospital, MA
"Update on Gastroesophageal Reflux Disease"
Medical Grand Rounds
2001 Lahey Clinic, Gastroenterology Rounds
"Clostridium difficile diarrhea: beyond antibiotics"
2002 St Elizabeth’s Hospital, Tufts Medical School, Brighton, MA,
Medical Grand Rounds
"Clostridium difficile associated diarrhea and colitis"
2002 Massachusetts General Hospital, Boston, MA
"Helicobacter pylori and the gastric epithelial cell: an intimate lifelong relationship"
Gastroenterology Grand Rounds
2002 New England Medical Center, Tufts University Medical School, MA
"Clostridium difficile: Recent advances in immunotherapy"
Gastroenterology Grand Rounds
2002 American Gastroenterology Association, Annual Meeting, San Francisco, CA
"Clostridium difficile colitis: Diagnosis and management"
"Meet-the-Professor" Session
2002 American Gastroenterology Association, Annual Meeting, San Francisco, CA
"Refractory Sprue"
Invited speaker, Clinical Symposium "Pathogenesis and Epidemiology of Celiac Disease"
2002 Visiting Professor, University of Cincinnati
Gastroenterology Grand Rounds
"Celiac Sprue: Uncovering the Iceberg"
2002 Visiting Professor, University of Cincinnati
Medicine Grand Rounds
"Clostridium difficile"
2003 Beth Israel Deaconess Medical Center, Boston
"Celiac sprue: Uncovering the iceberg"
Medicine Grand Rounds
2003 Veterans Administration Hospital, West Roxbury, Boston, Massachusetts.
"The difficult Clostridium"
Medicine Grand Rounds
2003 ClosPath 2003 – International Conference on Clostridial Pathogenesis
Woods Hole, Massachusetts.
"Clostridium difficile: Protective immunity and immunization"
Invited Speaker
2003 Visiting Professor, University of Connecticut Medical School
Gastroenterology Grand Rounds
"Celiac Disease"
2003 Massachusetts General Hospital
Department of Pediatric Gastroenterology & Nutritions
"Inhibition of NF-kB and other beneficial effects of moldy fruit"
Invited speaker
2003 Yale Medical School, New Haven
Department of Gastroenterology & Hepatology
"Clostridium difficile beyond antibiotics: probiotics & immunity"
Visiting Professor / Invited Speaker
2003 Massachusetts General Hospital, Boston, MA
"Clostridium difficile: Immunity & Immunization"
Gastroenterology Grand Rounds
2004 North Carolina
"Clostridium difficile: toward an effective vaccine." Acambis Scientific Advisory Board Meeting
2004 Brown University Medical Center, Rhode Island
"The difficult Clostridium."
Gastroenterology Grand Rounds
2004. BIDMC, Boston
"Human clinical studies on passive and active immunization against Clostridium difficile."
Gastroenterology Pathophysiology of Disease Lecture Series
2004 San Francisco, CA.
"Celiac sprue: an emerging epidemic?"
American Gastroenterology Association Spring Postgraduate Course
2004 Wellesley, MA
"Celiac disease: diagnosis and treatment."
Keynote speaker: Healthy Villi: Metropolitan Boston Celiac Disease and Dermatitis Herpetiformis Support Group.
2004 Barnstable, MA
"Celiac Disease: A Diagnostic Algorithm".
Lahey Clinic Gastroenterology Review
2004 Massachusetts Biologics Laboratory, University of Massachusetts
"Immunity to Clostridium difficile and options for passive immunotherapy."
2004 Bethesda, MD
"Diagnosis of Celiac Disease."
NIH Consensus Development Conference on Celiac Disease
2005 Brigham & Women’s Hospital, Boston, MA
"Clostridium difficile: Infection & Immunity".
Gastroenterology Grand Rounds
2005 Boston University Medical Center, Boston, MA
"Clostridium difficile: Immunity & Immunization". Pathology Grand Rounds
2005 Chicago
"Clostridium difficile: new approaches to a difficult pathogen."
Salix Scientific Advisory Board Meeting
2005 Winthrop University Hospital, Mineola, Long Island, NY
"Clostridium difficile: Immunity and New Treatment Approaches."
Gastroenterology Grand Rounds
2005 University of Illinois at Chicago, Chicago, IL
"Clostridium difficile: Immunity and Immunization." Internal Medicine Grand Rounds
BIBLIOGRAPHY
A. Original Articles
1. O'Donnell D, Kelly CP, Cotter P, Clancy L. Use of oxygen-driven nebulizer delivery systems for beta-2 agonists in chronic bronchitis. Ir J Med Sc 1985;154;198-200.
2. Kelly CP, Kennedy NP, Nolan M, Prichard JS, Clancy L. Transbronchial lung biopsy via flexible fibreoptic bronchoscopy: Review of 108 cases. Ir Med J 1985,78;350-2.
3. Kelly CP, England R, Mc Donald G, Weir DG. Suloctidil hepatitis. Ir J Med Sc 1987, 156; 290-1.
4. Kelly CP, O'Donnell D, West B, Gallagher N, Clancy L. Small cell and squamous cell lung carcinomas: Sequential occurrence at a single site. Thorax 1987, 42; 821-2.
5. Nolan N, Kelly CP, Humphreys H, O'Connor R, Walsh T, Weir DG, O'Brian S. An epidemic of pseudomembranous colitis: Importance of person to person spread. Gut 1987, 28; 1467-73.
6. Thakore JH, Kelly CP, Prichard JS. Campylobacter enteritis in a pregnant woman with hypogammaglobulinemia. Ir Med J 1989, 82; 165.
7. Gallagher RB, Feighery C, Weir DG, Kelly CP, Whelan CA. Studies on the interaction between a-gliadin, HLA and T cell receptor molecules in coeliac disease. Clin Exp Immunol 1989, 74: 413-18.
8. Kelly CP, Johnston CF, Nolan N, Keeling PWN, Weir PWN. Necrolytic migratory erythema with elevated plasma enteroglucagon in celiac disease. Gastroenterology 1989;96:1350-53.
9. Kelly CP, Tyrrell DNM, McDonald GSA, Whitehouse DB, Prichard JS. Heterozygous FZ alpha1-antitrypsin deficiency associated with severe emphysema and hepatic disease: case report and family study. Thorax 1989;44:758-59.
10. Gallagher RB, Kelly CP, Neville N, Sheils O, Weir DG, Feighery CF. Compliment activation within the coeliac small intestine is localised to Brunner's glands. Gut 1989;30:1568-73.
11. Nunes DP, Kelly CP, Nolan NPM, O`Connor MP, Weir DG. Fasting breath hydrogen, small intestinal bacterial overgrowth and intestinal transit in coeliac disease. Eur J Gastroenterol Hepatol 1991;3:313-319.
12. Kelly CP, Feighery CF, Gallagher RB, Gibney M, Weir DG. Mucosal and systemic IgA anti-gliadin antibody in celiac disease: Contrasting patterns of response in serum, saliva, and intestinal secretions. Dig Dis Sci 1991;36:743-751.
13. Leung DYM, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991;118:633-637.
14. Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Human colonic aspirates containing IgA antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 1992;102:35-40.
15. Kelly CP, Keane JC, Orellana J, Schroy PC, Yang S, LaMont JT, Brady HR. Human colon cancer cells express the cell adhesion molecule ICAM-1 in vivo and sup.ort LFA-1 dependent lymphocyte adhesion in vitro. Am J Physiol 1992;263:G864-G870.
16. Pothoulakis C, Kelly CP, Joshi MA, Gao N, Keane JC, Castagliuolo I, LaMont JT. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993;104:1108-1115.
17. Pothoulakis C, Karmeli F, Kelly CP, Eliakim R, Joshi MA, Keane JC, Castagliuolo I, LaMont JT, Rachmilewitz D. Ketotifen inhibits Clostridium difficile toxin A induced enteritis in rat ileum. Gastroenterology 1993;105:701-707.
18. Castagliuolo I, LaMont JT, Letourneau R, Kelly C, Keane JC, Jaffer A, Theoharides TC, Pothoulakis C. Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology 1994;107:657-665.
19. Kelly CP, Becker S, Linevsky JK, Joshi MA, Keane JC, Dickey BF, LaMont JT, Pothoulakis C. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 1994;93:1257-1265.
20. Kelly CP, Keates S, Siegenberg D, Linevsky JK, Pothoulakis C, Brady HR. IL-8 secretion and neutrophil activation by HT29 human colonic epithelial cells. Am J Physiol, 1994;267:G991-997.
21. Kelly CP, Vavva F, Castagliuolo I, Bostwick E, Keates S, LaMont JT, Pothoulakis C. Anti-Clostridium difficile bovine immunoglobulin concentrate blocks cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrobial Agents & Chemotherapy 1996;40:373-379.
22. Pothoulakis C, Galili U, Castagliuolo I, Kelly CP, Nikulasson S, Dudeja PK, Brasitus TA, LaMont JT. A human antibody binds to a-galactose receptors and mimics the effects of Clostridium difficile toxin A in rat colon. Gastroenterology 1996;110:1704-1712.
23. Pothoulakis C, Gilbert RJ, Cladaras C, Castagliuolo I, Semenza G, Hitti Y, Montcrief JS, Linevsky J, Kelly CP, Nikulasson S, Desai HP, Wilkins TD, LaMont JT. Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest 1996;98:641-649.
24. Kelly CP, Chetham S, Keates S, Bostwick E, Pothoulakis C, LaMont JT. C. difficile toxin neutralizing activity in human feces after oral anti-C. difficile bovine immunoglobulin concentrate. Antimicrobial Agents & Chemotherapy 1997;41:236-241.
25. Castagliuolo I, Keates AC, Qiu BS, Kelly CP, Nikulasson S, Leeman SE, Pothoulakis C. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci 1997;94:4788-4793.
26. Castagliuolo I, Kelly CP, Qiu BS, Nikulasson ST, LaMont JT, Pothoulakis C. IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol 1997;273:G333-G341.
27. J Salcedo, Keates S, Pothoulakis C, Castagliuolo I, LaMont JT, Kelly CP. Intravenous gamma globulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366-370.
28. Keates S, Keates A, Mizoguchi E, Bhan A, Kelly CP. Enterocytes are the primary source of the neutrophil-activating chemokine ENA-78 in normal colon and ulcerative colitis. Am J Physiol 1997;273:G75-G82.
29. Keates S, Hitti Y, Upton M, Kelly CP. Helicobacter pylori infection activates NF-_B in gastric epithelial cells. Gastroenterology 1997;113:1099-1109.
30. Linevsky JK, Pothoulakis C, Keates S, Warny M, Keates A, LaMont JT, Kelly CP. IL-8 production and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol 1997;273:G1333-G1340.
31. Castagliuolo I, Keates AC, Qiu BS, Shuck K, Kelly CP, Nikulasson ST, LaMont JT, Pothoulakis C. C. difficile toxin A stimulates enterocyte and macrophage production of the chemokine MIP-2 in rat ileum. J Immunol 1998;160:6039-6045.
32. Bliss CM, Golenbock DT, Keates S, Linevsky JK, Kelly CP. Helicobacter pylori lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human monocytes. Infection and Immunity 1998;66:5357-5363.
33. Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT, Pothoulakis C, Kelly CP. Bovine Immunoglobulin Concentrate-C. difficile retains C. difficile toxin neutralizing activity after passage through the human stomach and small intestine. Gut 1999;44:212-217.
34. Warny M, Kelly CP. Monocytic cell necrosis is mediated by potassium depletion and caspase-like proteases. Am J Physiol 1999;276:C717-724.
35. Keates S, Keates AC, Warny M, Peek RM Jr, Murray PG, Kelly CP. Differential activation of mitogen-activated protein kinases in AGS gastric epithelial cells by cag+ and cag- Helicobacter pylori. J Immunol 1999;163:5552-5559.
36. Warny M, Keates AC, Keates S, Castagliuolo I, Zachs JK, Aboudola S, Qamar A, Pothoulakis C, LaMont JT, Kelly CP. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest 2000;105:1147-1156.
37. Michetti M, Kelly CP, Kraehenbuhl J-P, Bouzourene H, Michetti P. Gastric mucosal alpha(4)beta(7)-integrin-positive CD4 T lymphocytes and immune protection against helicobacter infection in mice. Gastroenterology 2000;119:109-118.
38. Keates AC, Castagliuolo I, Cruickshank WW, Qiu B, Arseneau K, Brazer W, Kelly CP. Interleukin-16 is up-regulated in Crohn’s disease and participates in TNBS colitis in mice. Gastroenterology 2000;119:972-982.
39. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. New Eng J Med 2000;342:390-397.
40. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-193.
41. Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, JT LaMont, Kelly CP. Saccharomyces boulardii stimulates an intestinal IgA immune response to Clostridium difficile toxin A in mice. Infection & Immunity 2001;69:2762-2765.
42. Warny M, Aboudola S, Robson SC, Sevigny J, Communi D, Soltoff SP, Kelly CP. P2Y6 Nucleotide Receptor Mediates Monocyte Interleukin-8 Production in Response to UDP or Lipopolysaccharide. J Biol Chem. 2001;276:26051-56.
43. Keates AC, Keates S, Kwon JH, Arseneau KO, Law DJ, Bai L, Merchant JL, Wang TC, Kelly CP. ZBP-89, Sp1 and Fuclear Factor-_B regulate Epithelial Neutrophil-Activating peptide-78 gene expression in Caco-2 human colonic epithelial cells. J Biol Chem 2001;276:43713-43722.
44. Zhao D, Keates AC, Kuhnt-Moore S, Moyer MP, Kelly CP, Pothoulakis C. Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem 2001;276:44464-44471.
45. Keates S, Sougioultzis S, Keates AC, Zhao D, Peek RM Jr, Shaw LM, Kelly CP. cag+ H. pylori induce transactivation of the EGF receptor in AGS gastric epithelial cells. J Biol Chem 2001; 276:48127-48134.
46. Tendler DA, Aboudola S, Zacks JK, O’Brien MJ, Kelly CP. Prolapsing mucosal polyps: an underrecognized form of colonic polyp. Am J Gastroenterol 2002;97:370-6.
47. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clinical Infectious Diseases 2002;34:346-53.
48. Farrell RJ, Menconi MJ, Keates AC, Kelly CP. P-glycoprotein-170 inhibition reduces cortisol and cyclosporin efflux from human intestinal epithelial cells and T-lymphocytes. Aliment Pharmacol Ther 2002;16:1021-1031.
49. Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J, Kelly CP, Monath TP, Michetti P. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002;51:634-40.
50. Sougioultzis S, Lee CK, Alsahli M, Banerjee S, Cadoz M, Schrader R, Guy B, Bedford P, Monath TP, Kelly CP, Michetti P. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002;21:194-201.
51. Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infection Control and Hospital Epidemiology 2002;23:653-659.
52. Aboudola S, Kotloff KL, Kyne K, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP. Clostridium difficile vaccine and IgG antibody response to toxin A. Infect Immun 2003;71:1608-10.
53. Zaman MM, Gelrud A, Junaidi O, Regan MM, Warny M, Shea JC, Kelly C, O'Sullivan BP, Freedman SD. Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin Diagn Lab Immunol. 2004;11:819-24.
54. Drudy D, Calabi E, Kyne L, Sougioultzis S, Kelly E, Fairweather N, Kelly C. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunology & Medical Microbiology 2004;41: 237-42.
55. Anton PM, O’Brien M, Kokkotou E, Einsenstein B, Michaelis A, Rothstein D, Paraschos S, Kelly CP, Pothoulakis C. Rifalazil treats and prevents relapse of Clostridium difficile – associated diarrhea in hamsters. Antimicrob Agents Chemother 2004;48: 3975-9.
56. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 2005;128:764-70.
57. Keates S, Keates AC, Nath S, Peek RM, Jr, Kelly CP. Transactivation of the EGFR by cag+ Helicobacter pylori induces upregulation of the early growth response gene Egr-1 in gastric epithelial cells. Gut 2005 (in press) – Gut online publication as 10.1136/gut.2005.066977.
58. Kwon JH, Keates AC, Anton-Gay P, Botero M, Goldsmith JD, Kelly CP. Topical antisense oligonucleotide therapy against LIX, an enterocyte-expressed CXC chemokine, reduces murine colitis. Am J Physiol (in press).
B. Reviews, Chapters, and Editorials
1. Kelly CP, Feighery CF, Gallagher RB, Weir DG. Diagnosis and treatment of gluten sensitive enteropathy. Stollerman GH editor. Advances in Internal Medicine, 1990, Vol 35, Year Book Medical Publishers, Chicago, p. 341-363.
2. Kelly CP, LaMont JT. Treatment of Clostridium difficile diarrhea and colitis. Wolfe MM editor. Gastrointestinal Pharmacotherapy. W B Saunders Co., Philadelphia, 1993, p.199-212.
3. Pothoulakis C, Castagliuolo I, Kelly CP, LaMont JT. Clostridium difficile-associated diarrhea and colitis: Pathogenesis and therapy. International Journal of Antimicrobial Agents 1993,3:17-32.
4. Kelly CP. Leukocyte adhesion in gastrointestinal inflammation. Walker WA editor. Current Opinion in Gastroenterology 1993;9:962-970.
5. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Eng J Med 1994;330:257-262.
6. Kelly CP. Growth of gastroenterologic knowledge during the twentieth century (Kirsner). N Eng J Med 1994;331:818 (Book review).
7. Kelly CP, Kelsey PB, Graeme-Cooke F. Antiendomysial antibodies and celiac disease. N Eng J Med 1994;331:1776-1777 (Correspondence).
8. Kelly CP. The difficult Clostridium: The clinical presentation and management of Clostridium difficile diarrhoea and colitis. Journal of the Irish Colleges of Physicians and Surgeons 1995;24:261-266.
9. Siegenberg D, Kelly CP, LaMont JT. Management of Clostridium difficile diarrhea and colitis. Contemporary Internal Medicine 1996.
10. Kelly CP. Immune response to Clostridium difficile infection. Eur J Gastroenterol Hepatol 1996;8:1048-1053.
11. Kelly CP. Coeliac Disease. P P Howdle (ed). Gastroenterology 1996;111:265-266 (Book review).
12. JK Linevsky, Kelly CP. Clostridium difficile colitis. La Mont JT, editor. Gastrointestinal Infections. Marcel Dekker Inc., New York, 1997 p. 293-325.
13. Kelly CP. Cell death and Clostridium difficile toxins: The murder weapon uncovered. Inflammatory Bowel Diseases 1997;3:177-178.
14. Kelly CP, Michetti P. Helicobacter pylori infection: Pathogenesis. Boedeker EC editor. Current Opinion in Gastroenterology 1998;14:57-63.
15. Kelly CP, LaMont JT. Clostridium difficile infection. Annual Review of Medicine, 1998;49:375-390.
16. Kyne L, Kelly CP. Prospects for a vaccine for Clostridium difficile. Biodrugs 1998;10:173-181.
17. Kelly CP, LaMont JT. Treatment of Clostridium difficile diarrhea and colitis. Wolfe MM editor. Therapy of Digestive Disorders. W B Saunders Co., Philadelphia, 2000, p. 513-522.
18. Kelly CP, LaMont JT. Bacterial infections of the colon. Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE, editors. Textbook of Gastroenterology, 3rd edition. J. B. Lipincott, Philadelphia, 2001.
19. Kelly CP, Michetti PM. Inflammatory Bowel Disease. Noble J, editor. Textbook of Primary Care Medicine. Mosby, Inc., St Louis, Missouri, 2001, p. 983-990.
20. Kyne L, Kelly CP. Therapy Update: Recurrent Clostridium difficile diarrhoea. Gut 2001:49:152-153.
21. Farrell RJ, Kelly CP. Diagnosis of Celiac Disease. Am J Gastroenterol, 2001;96:3237-46.
22. Kyne L, Farrell R, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am 2001;30:753-77.
23. Farrell RJ, Kelly CP. Celiac Sprue and Refractory Sprue. Feldman, Friedman, and Sleisenger, editors. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease, 7th edition. W B Saunders Co., Philadelphia, 2002, p. 1817-1841.
24. Elliott SN, Ernst PB, Kelly CP. Molecular inflammation. Current Opinion in Gastroenterology: The year in Helicobacter pylori 2001.
25. Cardenas A, Kelly CP. Celiac Sprue. Seminars in Gastrointestinal Disease 2002;13:232-244.
26. Farrell RJ, Kelly CP. Celiac Sprue. N Eng J Med 2002;346:180-188.
27. Farrell RJ, Kyne L, Kelly CP. Pseudomembranous colitis and Clostridium difficile infection. Targan, Shanahan, Karp, editors. Inflammatory Bowel Disease: From Bench to Bedside. Kluwer Academic Publishers, Dordtrecht, The Neatherlands, 2003, p. 823-844.
28. Warny M, Kelly CP. Pathogenicity of Clostridium difficile toxins. G Hecht editor. Microbial Pathogenesis and the Intestinal Epithelial Cell. ASM Press, Washington, D.C., 2003, p 503-524.
29. Kwon JH, Kelly CP. Clostridium difficile and antibiotic-associated diarrhea. Bayless & Diehl eds. Advanced Therapy in Gastroenterology and Liver Disease. BC Decker Inc., Ontario, Canada, 2005, p. 302-6.
30. Kelly CP, LaMont JT. Treatment of Clostridium difficile diarrhea and colitis. Wolfe MM editor. Therapy of Digestive Disorders. 2nd edition. W B Saunders Co., Philadelphia. 2006, p 733-744.
31. Tummala S, Keates S, Kelly CP. Update on the immunologic basis of H. pylori gastritis. Current Opinion in Gastroenterology. 2004:20;592-597.
32. Fefferman D.S., Kelly CP. Anorectal Pain. Tierney and Henderson editors. The Patient History: Evidence-based approach. Lange, New York, 2005, p. 337-345.
33. Cardenas A, Patel S, Kelly CP. Celiac disease. Weinstein, Hawkey, Bosch editors. Clinical Gastroenterology and Hepatology. Elsevier Mosby, 2005, p. 281-288.
34. Schuppan D, Dennis MD, Kelly CP. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management. Nutr Clin Care. 2005;8:54-69.
35. Guandalini [Guiadalini] S, Kelly CP. Toward optimal health: interview on celiac disease by Jodi R Godfrey. J Womens Health (Larchmt). 2005;14:110-6.
36. Farrell RJ, Kelly CP. Celiac Sprue and Refractory Sprue. Feldman, Friedman, and Brandt, editors. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease, 8th edition. W B Saunders Co., Philadelphia, (in press).
37. Kelly CP, LaMont JT. Pseudomembranous Colitis and Antibiotic-Associated Diarrhea. Feldman, Friedman, and Brandt, editors. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease, 8th edition. W B Saunders Co., Philadelphia, (in press).
C. Clinical Communications
1. O’Donnell D, Kelly CP. Resolution of membranous glomerulonephropathy after chemotherapy for lung cancer. Br Med J 1984, 288; 194.
2. Kelly CP, O’Connor R, Weir DG. Pseudomembranous colitis and cefotaxime. Lancet 1986, I; 102-3.
3. Kelly CP. Neonatal external cardiac massage. Lancet 1986, II; 168-9 (Letter).
4. Kelly CP, Weir DG. Disseminated intravascular coagulopathy and pseudomembranous colitis. Br Med J 1986, 292; 1050.
5. O’Connor RA, Kelly CP, Walsh TN, Weir DG. Hospital outbreaks of Clostridium difficile colitis. Lancet 1986,II;751.
6. Kelly CP, O’Shea B, Kelly J, C Feighery C, Weir DG. Atopy and childhood coeliac disease. Lancet 1987, II; 109 (Letter).
7. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Eng J Med 1994, 330: 1754-55. (Correspondence)
8. Kelly CP, Graeme-Cooke FM. A 74-year-old woman with worsening chronic diarrhea, weight loss, and abdominal pain (Case records of the Massachusetts General Hospital). N Eng J Med 1994;331:383-390.
9. Kelly CP. Meta-analysis (A Limerick). Lancet 1997;350:1182.
10. Cardenas A, Kelly C. Menetrier’s disease. Gut. 2004;53:330,338.
D. Thesis
Coeliac disease: Non-invasive tests to screen for gluten sensitive enteropathy and to monitor response to dietary therapy.
M.D., Dublin University, Trinity College, 1995
E. Nonprint Materials
1. Kelly CP, LaMont JT. Treatment of recurrent Clostridium difficile infection. LaMont, Chopra editors, Up To Date in Gastroenterology & Hepatology,Volume 8, Up To Date Inc, 1998-2000.
2. Kelly CP. Use of serum antibodies to diagnose celiac disease. LaMont, Chopra editors, Up To Date in Gastroenterology & Hepatology, Up To Date Inc, 1998-2001.
3. Kelly CP. Celiac disease: Patient Information. LaMont, Chopra editors, Up To Date in Gastroenterology & Hepatology, Up To Date Inc, 2001.
|
